Agregátor RSS
Unpatched OnePlus Flaws Let Installed Android Apps Gain Root Without Permissions
Unpatched OnePlus Flaws Let Installed Android Apps Gain Root Without Permissions
ThreatsDay: AI Search Poisoning, AI Coding Tool Leaking Repos, One-Click Code Execution and 13 More Stories
ThreatsDay: AI Search Poisoning, AI Coding Tool Leaking Repos, One-Click Code Execution and 13 More Stories
Exposed GitLab project email addresses let attackers push code
Variabilní clona nových iPhonů se nemá ráda s MagSafe příslušenstvím. Na svém telefonu to radši nezkoušejte
A Digital Cell Predicts Which Drugs Will Be Most Effective in Deadly Breast Cancer
The AI-powered virtual cell tailors treatments for breast cancer based on samples of each patient’s tumor.
Tailoring cancer treatments is a science and an art.
The same type of tumor can behave very differently from one person to the next, and a drug that works for one patient may fail in another. The uncertainty stacks up when multiple drugs enter the mix. Trial and error is often unavoidable. Meanwhile, cancers keep growing and compounding side effects can plague already beleaguered bodies.
Researchers have long sought to speed up the process of tailoring treatments to patients, and AI might lend a hand. This month, a Chinese team developed an AI-based virtual cell for triple-negative breast cancer—a challenging form of the disease that often evades standard treatments—to predict how individuals will respond to different drugs.
Rather than reconstructing every detail of a cell’s inner workings, the virtual cell focused on just proteins. Trained on a massive, curated dataset tracking protein changes before and after drug treatments, the model outperformed existing drug-tailoring approaches and discovered new combinations that could work even better.
The underlying AI, called ProteinTalks, was also readily adapted to predicting drug responses in other cancers, hinting at a broader reach beyond breast cancer.
That’s not to say the virtual cell is ready for prime time. Researchers tested its predictions in patient-derived cells in lab dishes, and the model can only evaluate two-drug combinations. Whether its recommendations translate into meaningful benefits must be tested in patients.
But the results offer a proof of concept: Virtual cells, even imperfect mimics of their biological counterparts, could one day help physicians find more effective treatments from the get-go.
“This is the first time that a virtual cell model goes out of the laboratory and is tested in a clinical scenario,” study author Tiannan Guo at Westlake University in Hangzhou, China told Nature.
Digital TwinsEvery cell is a buzzing city. Proteins zip around a crowded interior, briefly grabbing onto one another to direct cell functions. Fatty molecules maintain the protective outer membrane, while mRNA carries genetic instructions to protein-making factories. All these workers relay feedback to the cell’s control center—the DNA-harboring nucleus—where these signals help switch genes on or off and keep the cell humming.
Recreating this complexity in digital form might sound like a fever dream. But AI is turning it into a scientific race. Unlike finicky biological cells, their virtual counterparts could slash the time and labor needed to run experiments, allowing researchers to test myriad ideas at breakneck speed.
Academia and industry are already chasing this goal.
In an interview, Google DeepMind co-founder Demis Hassabis said the team is developing an AI-powered virtual nucleus, which offers a relatively self-contained starting point from which to build a whole virtual cell. The Chan Zuckerberg Initiative is partnering with Nvidia to develop tools and AI models that would help run and evaluate virtual cells. Meanwhile, the Science for Life Laboratory received funding for its ambitious AlphaCell program, which aims to create AI models that predict how cells work and adapt in health and disease.
Earlier efforts to build virtual cells relied on transcriptomics—that is, a snapshot of gene activity—across single cells. But these measurements don’t necessarily reflect what a protein is doing at any given time and can miss changes.
The new study takes a different route, cutting out the middleman. Instead of inferring protein activity from which genes are active at any given moment, the team trained their AI model directly on the proteins themselves and used the model to power a new type of virtual cell.
The Protein WhispererA long-standing roadblock for protein-based AI models is the lack of comprehensive datasets.
To tackle the problem, the team treated 18 immortalized breast cancer cell types—16 of them triple-negative—with 63 FDA-approved anticancer drugs and 59 common drug combinations. They then measured thousands of proteins at four timepoints: before treatment and at 6, 24, and 48 hours afterwards. Altogether, the experiments generated more than 38 million protein measurements, along with cell-survival data, now available in an open-source database.
It’s “one of the largest…resources reported to date,” wrote the team.
ProteinTalks, the AI virtual cell trained on this dataset, could deal with several aspects of cancer treatment.
First, it found over 800 proteins whose levels changed after each drug treatment and zeroed in on a rapidly shifting subset. These could “act as sentinels” of an early drug response, the authors wrote. Most behaved as expected. Some drugs disrupted the cell’s structural scaffolding; others interfered with DNA repair or growth, ultimately causing cells to wither.
Over time, tumors can evade treatments, resulting in their return or spread. The model flagged several protein suspects likely involved in this process. These might serve as signals of resistance or drug targets for tackling it.
The AI could also generalize. When challenged with 81 drugs it hadn’t seen during training, ProteinTalks predicted protein changes with 88 percent accuracy, outperforming several previous models.
The team then trained it on more than 900 drug mixes to see whether it could help identify promising pairs. The virtual cell gave higher scores to combinations that had already been validated experimentally and used in the clinic. This “sanity check” suggests the AI isn’t simply hallucinating results but could generate valuable insights.
Finally, the team asked whether the model could help prioritize treatments for individual patients. They screened 3,000 approved, clinical-stage molecules using proteomics data from three people with the disease. The model identified regimes that matched treatments that had kept the disease at bay—and suggested three additional molecules that could be even more effective. The predictions worked out. When tested in cancer cell samples from patients, the drugs inhibited growth at lower doses than standard therapies.
Although trained on breast cancer, ProteinTalks could also pivot to other tumor types when fed cancer-specific proteomics data. In lab-grown melanoma, colorectal, lung, and pancreatic cancer cells, it found more than 5,100 protein changes, including subsets unique to each cancer type ready for further analysis.
As with other virtual cells, ProteinTalks is still a prototype. Given the hope, and hype, surrounding these models, the team emphasizes that its predictions will need to be tested in animal models and, eventually, clinical trials. Its suggestions could point the way toward better treatments for stubborn cancers, or they could turn out to be AI flights of fancy—drug combinations that look promising on paper but make little biological sense.
There’s another limitation. ProteinTalks doesn’t account for protein interactions, either with one another or with DNA and other biomolecules. Drugs could disrupt these temporary biological “handshakes,” potentially triggering effects that ripple through the cell.
Combining ProteinTalks with AI based on gene activity could add another layer of information and spruce up its predictions. The virtual cell is still a long way from a true digital twin, but piece by piece, the dream is getting closer.
The post A Digital Cell Predicts Which Drugs Will Be Most Effective in Deadly Breast Cancer appeared first on SingularityHub.
Decades-old file security flaws found in Android, Linux, macOS, and Windows
Nejvýkonnější přílivová turbína na světě vypadá jako ze Star Wars. Peníze se hrnou, projekty jedou, ve vývoji je ještě větší monstrum
CVE flood pushes Ubuntu onto weekly kernel release cycle
Microsoft integrates SOC capabilities with Defender for enterprises
Microsoft 365 E5 and E7 customers can now run security information and event management (SIEM) inside Microsoft Defender at no extra license cost.
Microsoft is delivering the capability through the Integrated Security Operations Center (ISOC) in Microsoft Defender, which combines SIEM with Defender’s existing XDR, threat intelligence, automation and AI tools in a single portal.
“Security cannot operate at AI speed when protection and operations are built as separate systems,” Rob Lefferts, corporate vice president of Microsoft Threat Protection, wrote in a blog post announcing ISOC. He said attackers now use AI agents to automate attacks at scale, and that every handoff between separate tools slows defenders down.
Until now, E5 and E7 included Defender XDR but not SIEM, which Microsoft sells separately as Microsoft Sentinel.
Under ISOC, logs from Microsoft’s own security products are available without ingestion charges. From Oct. 1, data ingested from third-party security tools and other outside sources will be metered at $2.40 per GB on a pay-as-you-go basis, Microsoft said in a technical blog post.
The company opened ISOC as a public preview, meaning it is not fully production-ready, on Sept. 23 and has not said when the preview phase will end. It is available to organizations with an active Microsoft Defender Suite and Microsoft 365 E5 or E7 license that do not already run Microsoft Sentinel, and has no minimum seat requirement.
For organizations whose security stack already runs largely on Microsoft, the trade is attractive, said Yih Khai Wong, senior research manager for security services research at IDC Asia/Pacific.
“Most telemetry already resides in Defender, Entra, and M365, so bundling Sentinel’s SIEM into E5/E7 effectively makes ingestion free, with no separate license needed to move and re-analyze data your own vendor already holds,” Wong said.
A benefit, not a product“ISOC is not a new standalone product,” Microsoft said in an FAQ accompanying the technical post. Its ISOC product page said capabilities such as workbooks and natural-language-to-SOAR automation “previously required a separate Sentinel purchase.”
According to the technical post, Microsoft began rolling out case management, workbooks and natural-language playbook generation to eligible customers’ Defender portals on Sept. 23, with no additional configuration required.
The included data covers Defender for Endpoint, Office 365, Identity, Cloud Apps and Cloud, plus Microsoft Entra ID Protection logs and Azure and Office 365 activity logs. Retention is 30 days during the preview, rising to 90 days on Nov. 15, the post added.
Everything else costsAnything beyond that requires an ISOC workspace, which needs an Azure subscription, according to Microsoft’s product documentation. The workspace unlocks more than 500 data connectors, user and entity behavior analytics (UEBA), CI/CD repositories and threat intelligence.
Wong said mixed environments face a different calculation. “For multicloud shops or organizations with significant non-Microsoft telemetry, this requires a real total cost-of-ownership comparison against current SIEM spend.”
The current preview excludes organizations with an active Sentinel workspace. Microsoft said nothing changes for existing Sentinel customers, and those meeting the licensing criteria can choose to move to ISOC from Nov. 15.
Consolidating identity, endpoint, productivity and security operations under one vendor can simplify investigations, Wong said, but it also “creates greater dependency on that vendor’s roadmap, pricing model, availability, and security resilience.”
CISOs running a separate SIEM face a genuine evaluation, not a quick swap, weighing migration effort, retraining of detection content, exit costs and contractual complexity, he added.
Sanchit Vir Gogia, chief analyst at Greyhound Research, advised enterprises interested in ISOC to “reproduce the organisation’s highest-value cross-vendor detections before replacing a mature SIEM,” warning that “Microsoft’s claim of more than 500 connectors establishes reach, not equal treatment of every source.”
Agents take the next stepMicrosoft’s Lefferts positioned ISOC as the foundation for the agent strategy Microsoft introduced alongside Project Perception in July.
Gogia questioned the premise that this requires a single vendor. “Microsoft has established a useful integration path. It has not established that one supplier is technically necessary for an agentic SOC,” he said. He noted that Project Perception remains invitation-only in limited public preview.
Microsoft has not published details on how agent actions within ISOC are logged, audited or reversed. Gogia said the critical threshold comes when agents gain authority to make changes, since changes to identity, endpoint or cloud policy “create a blast radius.” He recommended distinct agent identities, narrow tool permissions and independent approval for consequential changes.
The agents themselves add attack surface, Wong warned. “Adversaries may attempt to manipulate the telemetry an agent relies on, poison contextual data, or use prompt injection techniques to influence agent behavior and decision-making,” Wong said.
“Microsoft has made integration easier to buy. The enduring test is whether customers retain the means to challenge and reverse it,” Gogia said.
Microsoft did not immediately respond to a request for comment.
This article first appeared on CSO.
Jamf in the age of agentic IT: An interview with CEO Beth Tschida
Jamf was a pioneer in Apple device management when it began in 2002. The company was ahead of its time: its founders could see that Apple had a future in the enterprise, but not many others saw it. Jamf now runs 35.2 million devices from 78,000 organizations. And it’s still looking to the future.
I spoke with Jamf CEO Beth Tschida, who joined me for a chat directly after her keynote speech at JNUC, Jamf’s big event for Mac admins, on September 23.
The AI-driven ecosystemTschida wasn’t there to rehash Jamf’s past for relevance in the present, but to share the company’s deep commitment to being where its customers are going to go. That means artificial intelligence, which in Jamf’s case involves weaving AI across its ecosystem of products, from setup to tech support, security, and beyond.
It’s not a new vision — you could argue that some early signs of its intention were visible when the company acquired ZecOps in 2022 — but time moves forward and the company has coalesced around a firm philosophy of how to use AI, where to use AI, and how AI should be deployed in a human-centric way for the benefit of its customers.
“AI runs better on Apple, and Apple runs better on Jamf,” Tschida told me. The next piece to that statement is to consider how AI can be effectively managed by IT, she added. “You have to be able to see it. You have to be able to govern it, and then you want to be able to harness it.”
This points directly to shadow AI, one of the big-picture problems IT has with AI at the moment as employees feed confidential data to the cloud-based AI models. Jamf’s response has been to create new frameworks IT can use to monitor use of AI across their managed fleets. These tools let IT identify use, manage use, or even stop use altogether.
“How can we look at that, see it, govern it, and harness it in the ways that AI is providing that opportunity, right at the endpoint?” Tschida said.
Precision modelingThe other component is pricing. Even when data is legitimately shared to AI, the cost of inferencing is high and getting higher. Jamf now offers tools to let IT monitor this use and the cost of it, enabling management to suggest lower cost or on-prem AI solutions for tasks where appropriate. After all, why would you pay for Fable when you can get your Apple device to help write that letter?
Tschida explained that part of Jamf’s response to AI costs is the inclusion of granular model controls, which let admins assign different teams access to different models, the idea being to prevent what she called “overmodeling” — the use of expensive high-reasoning models for tasks that lightweight models can handle.
“You have to understand what the need is. You must lay it out there in a governed way. Human in the loop and then you harness it,” she said.
The Mac advantageBut the Jamf vision doesn’t end with AI management; it extends to making active use of the tech. In this case the company has introduced AI-powered tech support for routine problems to free up staff time. There are two strands to this approach: More obviously, easy to access tech support should reduce time spent on routine problem solving, but another compelling aspect of this evolution is the move toward proactive device health.
Traditionally, IT has been reactive: a user experiences slowness, they eventually file a ticket, and IT fixes it. But many users simply “endure” suboptimal performance without ever reporting it, Tschida explained. “A lot of times, users don’t even raise a ticket. They just endure.”
That was then, but the future looks different. “We believe that we now have the right telemetry to look at device health,” Tschida said. “You’re really moving ahead of problems. Users don’t even raise a ticket… you can help them optimize it without them knowing it.”
With over 35 million devices now managed using Jamf, the origin story of the company seems further ahead of its time now than ever. Apple’s enterprise product marketing lead, Jeremy Butcher, appeared at one point during Tschida’s keynote to talk about where Apple now is in the enterprise. He pointed to data that Macs generate 55% fewer help tickets than Windows systems. He confirmed that the MacBook Neo has accelerated enterprise growth for the platform, and pointed out that more Apple devices are purchased in enterprise than any other brand.
With so much energy behind Apple’s platforms, what has Tschida been seeing?
“We know that Anthropic and other companies, they tend to deploy for Mac first. The developers are mostly running Macs. That’s what they prefer to be on, and they’re at the forefront of agentic AI.”
The thing about the growing enterprise Apple ecosystem is that no single company can build the perfect set of solutions for every enterprise. Part of Jamf’s response to this has been the creation of platform APIs, which customers and partners can use to extend the platform to meet their needs. “I love a good API because it allows you to run a road map way faster,” Tschida said.
Former Jamf CEO Dean Hager used to say, “When Apple innovates, Jamf celebrates.”
His successor echoes his point, with a focus on what Jamf can do for its customers. “Our job is to make sure that Apple runs better with Jamf,” she said. “We’re scaling it, we’re securing it, and we’re making sure that you can… first see it, and govern it, and then harness what you can get from it in a way that’s helpful for our customers.”
Local intelligence, global scaleA second aspect to governance is around sovereign, private, and/or on-premises AI. I asked Tschida what her customers are saying. “There will be some that look at the benefit if you can run at least some of your workflows locally,” she said. “There’s a tokenomics piece of it. There’s a privacy piece of it. There’s a sovereignty piece of it.”
Whatever the motivation, for Jamf the question remains, “How can you determine what we can do and help you do, locally on device, and build that so you can run it at scale? That’s where we’re focused.”
I walked away from the interview feeling a vision for Apple in the enterprise in which IT is augmented by smart tech infrastructure: Macs that request support before users know they need it, systems that self-identify bottlenecks or wasted resources such as over-generous token consumption and let IT take steps. A more intelligent enterprise infrastructure, equipped with real-time awareness, self-reliant with little to no cloud exposure.
For Apple, Jamf, and certainly for the Mac, that seems like several giant steps since the foundation of Jamf in 2002. AI in IT is an accelerant, and Jamf is working with it. “We are doing our best to run at the speed of AI,” said Tschida.
Now please subscribe to my daily, human-curated Apple-related news headline feed at The Core, or follow me on BlueSky, LinkedIn, or Mastodon.
Hraní zdarma výměnou za reklamu? Microsoft si patentuje technologii, která vás nenaštve
Placeholder third-party[.]com Referenced Across 1,700+ Repositories Now Serves Malicious Content
Placeholder third-party[.]com Referenced Across 1,700+ Repositories Now Serves Malicious Content
Recenze hry The Alighieri Circle: Dante's Bloodline. Večerní procházka peklem. Nic víc, nic míň
Someone went shopping in ASUS's eShop – for customer data
Gemini hacknulo tři skutečné firmy. Někdo mu při testu omylem otevřel dveře na internet
Hacked Ukrainian Sites Serve Fake Cloudflare ClickFix Lures for Psychedelic Stealer
Hacked Ukrainian Sites Serve Fake Cloudflare ClickFix Lures for Psychedelic Stealer
- « první
- ‹ předchozí
- …
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- …
- následující ›
- poslední »



